Baseline characteristics of participants of the cardiovascular outcome study
| Characteristic, N (%) . | Group 1, treatment (n = 19 952) . | Group 1, control (n = 33 947) . | Group 1a, treatment (n = 3486) . | Group 1a, control (n = 14 983) . | Group 1b, treatment (n = 16 466) . | Group 1b, control (n = 18 964) . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Female | 15 588 (78.1) | 21 350 (62.9) | 2823 (81.0) | 9502 (63.4) | 12 765 (77.5) | 11 848 (62.5) |
| Male | 4364 (21.9) | 12 597 (37.1) | 663 (19.0) | 5481 (36.6) | 3701 (22.5) | 7116 (37.5) |
| Age, y | ||||||
| 51-60 | 5141 (25.8) | 10 991 (32.4) | 495 (14.2) | 3141 (21.0) | 4646 (28.2) | 7850 (41.4) |
| 61-70 | 6687 (33.5) | 10 309 (30.4) | 895 (25.7) | 4200 (28.0) | 5792 (35.2) | 6109 (32.2) |
| 71-80 | 5185 (26.0) | 8250 (24.3) | 1125 (32.3) | 4654 (31.1) | 4060 (24.7) | 3596 (19.0) |
| 81-90 | 2533 (12.7) | 3895 (11.5) | 813 (23.3) | 2631 (17.6) | 1720 (10.4) | 1264 (6.7) |
| 91+ | 406 (2.0) | 502 (1.5) | 158 (4.5) | 357 (2.4) | 248 (1.5) | 145 (0.8) |
| Median (lower quartile-upper quartile) | 67 (60-76) | 66 (59-75) | 73 (65-81) | 71 (62-79) | 66 (60-75) | 63 (57-71) |
| Ethnicity | ||||||
| Asian | 311 (1.6) | 498 (1.5) | 28 (0.8) | 175 (1.2) | 283 (1.7) | 323 (1.7) |
| Black | 52 (0.3) | 127 (0.4) | 8 (0.2) | 49 (0.3) | 44 (0.3) | 78 (0.4) |
| Mixed | 2937 (14.7) | 5042 (14.9) | 425 (12.2) | 2138 (14.3) | 2512 (15.3) | 2904 (15.3) |
| Other | 89 (0.4) | 178 (0.5) | 20 (0.6) | 81 (0.5) | 69 (0.4) | 97 (0.5) |
| White | 6197 (31.1) | 10 840 (31.9) | 1059 (30.4) | 4674 (31.2) | 5138 (31.2) | 6166 (32.5) |
| No information | 10 366 (52.0) | 17 262 (50.8) | 1946 (55.8) | 7866 (52.5) | 8420 (51.1) | 9396 (49.5) |
| Location | ||||||
| London | 1219 (6.1) | 2154 (6.3) | 182 (5.2) | 830 (5.5) | 1037 (6.3) | 1324 (7.0) |
| Midlands and East | 2972 (14.9) | 4285 (12.6) | 482 (13.8) | 1653 (11.0) | 2490 (15.1) | 2632 (13.9) |
| North | 2889 (14.5) | 4573 (13.5) | 463 (13.3) | 2068 (13.8) | 2426 (14.7) | 2505 (13.2) |
| Northern Ireland | 1380 (6.9) | 1963 (5.8) | 242 (6.9) | 984 (6.6) | 1138 (6.9) | 979 (5.2) |
| Scotland | 2069 (10.4) | 4523 (13.3) | 385 (11.0) | 2139 (14.3) | 1684 (10.2) | 2384 (12.6) |
| South | 4626 (23.2) | 8900 (26.2) | 816 (23.4) | 3700 (24.7) | 3810 (23.1) | 5200 (27.4) |
| Wales | 3212 (16.1) | 5226 (15.4) | 647 (18.6) | 2630 (17.6) | 2565 (15.6) | 2596 (13.7) |
| No information | 1585 (7.9) | 2323 (6.8) | 269 (7.7) | 979 (6.5) | 1316 (8.0) | 1344 (7.1) |
| Smoker status | ||||||
| Smoker | 1510 (7.6) | 2548 (7.5) | 206 (5.9) | 985 (6.6) | 1304 (7.9) | 1563 (8.2) |
| Past smoker | 6236 (31.3) | 10 680 (31.5) | 1063 (30.5) | 4802 (32.0) | 5173 (31.4) | 5878 (31.0) |
| Non-smoker | 12 174 (61.0) | 20 525 (60.5) | 2206 (63.3) | 9101 (60.7) | 9968 (60.5) | 11 424 (60.2) |
| No information | 32 (0.2) | 194 (0.6) | 11 (0.3) | 95 (0.6) | 21 (0.1) | 99 (0.5) |
| Comorbidities | ||||||
| Asthma | 1936 (9.7) | 1938 (5.7) | 311 (8.9) | 879 (5.9) | 1625 (9.9) | 1059 (5.6) |
| Chronic kidney disease | 1895 (9.5) | 73 (0.2) | 266 (7.6) | 39 (0.3) | 1629 (9.9) | 34 (0.2) |
| Chronic obstructive pulmonary disease | 752 (3.8) | 689 (2.0) | 116 (3.3) | 347 (2.3) | 636 (3.9) | 342 (1.8) |
| Dementia | 108 (0.5) | 36 (0.1) | 31 (0.9) | 19 (0.1) | 77 (0.5) | 17 (0.1) |
| Depression | 2827 (14.2) | 2238 (6.6) | 409 (11.7) | 963 (6.4) | 2418 (14.7) | 1275 (6.7) |
| Diabetes | 1940 (9.7) | 1305 (3.8) | 343 (9.8) | 695 (4.6) | 1597 (9.7) | 610 (3.2) |
| Dyslipidemia | 2287 (11.5) | 1782 (5.2) | 410 (11.8) | 905 (6.0) | 1877 (11.4) | 877 (4.6) |
| Heart disease | 10 029 (50.3) | 10 261 (30.2) | 1783 (51.1) | 5009 (33.4) | 8246 (50.1) | 5252 (27.7) |
| Hypertension | 10 481 (52.5) | 11 463 (33.8) | 1986 (57.0) | 5845 (39.0) | 8495 (51.6) | 5618 (29.6) |
| Rheumatoid arthritis | 314 (1.6) | 270 (0.8) | 61 (1.7) | 115 (0.8) | 253 (1.5) | 155 (0.8) |
| Hormone levels | ||||||
| Low-normal fT4 levels | 9761 (48.9) | 17 122 (50.4) | 1245 (35.7) | 7014 (46.8) | 8516 (51.7) | 10 108 (53.3) |
| High-normal fT4 levels | 10 191 (51.1) | 16 825 (49.6) | 2241 (64.3) | 7969 (53.2) | 7950 (48.3) | 8856 (46.7) |
| TSH, median (lower quartile-upper quartile) | 3.9 (2.3-5.0) | 4.8 (4.3-5.5) | 3.6 (2.7-4.4) | 4.3 (4.1-4.5) | 4.0 (3.0-5.1) | 5.4 (4.9-6.2) |
| Characteristic, N (%) . | Group 1, treatment (n = 19 952) . | Group 1, control (n = 33 947) . | Group 1a, treatment (n = 3486) . | Group 1a, control (n = 14 983) . | Group 1b, treatment (n = 16 466) . | Group 1b, control (n = 18 964) . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Female | 15 588 (78.1) | 21 350 (62.9) | 2823 (81.0) | 9502 (63.4) | 12 765 (77.5) | 11 848 (62.5) |
| Male | 4364 (21.9) | 12 597 (37.1) | 663 (19.0) | 5481 (36.6) | 3701 (22.5) | 7116 (37.5) |
| Age, y | ||||||
| 51-60 | 5141 (25.8) | 10 991 (32.4) | 495 (14.2) | 3141 (21.0) | 4646 (28.2) | 7850 (41.4) |
| 61-70 | 6687 (33.5) | 10 309 (30.4) | 895 (25.7) | 4200 (28.0) | 5792 (35.2) | 6109 (32.2) |
| 71-80 | 5185 (26.0) | 8250 (24.3) | 1125 (32.3) | 4654 (31.1) | 4060 (24.7) | 3596 (19.0) |
| 81-90 | 2533 (12.7) | 3895 (11.5) | 813 (23.3) | 2631 (17.6) | 1720 (10.4) | 1264 (6.7) |
| 91+ | 406 (2.0) | 502 (1.5) | 158 (4.5) | 357 (2.4) | 248 (1.5) | 145 (0.8) |
| Median (lower quartile-upper quartile) | 67 (60-76) | 66 (59-75) | 73 (65-81) | 71 (62-79) | 66 (60-75) | 63 (57-71) |
| Ethnicity | ||||||
| Asian | 311 (1.6) | 498 (1.5) | 28 (0.8) | 175 (1.2) | 283 (1.7) | 323 (1.7) |
| Black | 52 (0.3) | 127 (0.4) | 8 (0.2) | 49 (0.3) | 44 (0.3) | 78 (0.4) |
| Mixed | 2937 (14.7) | 5042 (14.9) | 425 (12.2) | 2138 (14.3) | 2512 (15.3) | 2904 (15.3) |
| Other | 89 (0.4) | 178 (0.5) | 20 (0.6) | 81 (0.5) | 69 (0.4) | 97 (0.5) |
| White | 6197 (31.1) | 10 840 (31.9) | 1059 (30.4) | 4674 (31.2) | 5138 (31.2) | 6166 (32.5) |
| No information | 10 366 (52.0) | 17 262 (50.8) | 1946 (55.8) | 7866 (52.5) | 8420 (51.1) | 9396 (49.5) |
| Location | ||||||
| London | 1219 (6.1) | 2154 (6.3) | 182 (5.2) | 830 (5.5) | 1037 (6.3) | 1324 (7.0) |
| Midlands and East | 2972 (14.9) | 4285 (12.6) | 482 (13.8) | 1653 (11.0) | 2490 (15.1) | 2632 (13.9) |
| North | 2889 (14.5) | 4573 (13.5) | 463 (13.3) | 2068 (13.8) | 2426 (14.7) | 2505 (13.2) |
| Northern Ireland | 1380 (6.9) | 1963 (5.8) | 242 (6.9) | 984 (6.6) | 1138 (6.9) | 979 (5.2) |
| Scotland | 2069 (10.4) | 4523 (13.3) | 385 (11.0) | 2139 (14.3) | 1684 (10.2) | 2384 (12.6) |
| South | 4626 (23.2) | 8900 (26.2) | 816 (23.4) | 3700 (24.7) | 3810 (23.1) | 5200 (27.4) |
| Wales | 3212 (16.1) | 5226 (15.4) | 647 (18.6) | 2630 (17.6) | 2565 (15.6) | 2596 (13.7) |
| No information | 1585 (7.9) | 2323 (6.8) | 269 (7.7) | 979 (6.5) | 1316 (8.0) | 1344 (7.1) |
| Smoker status | ||||||
| Smoker | 1510 (7.6) | 2548 (7.5) | 206 (5.9) | 985 (6.6) | 1304 (7.9) | 1563 (8.2) |
| Past smoker | 6236 (31.3) | 10 680 (31.5) | 1063 (30.5) | 4802 (32.0) | 5173 (31.4) | 5878 (31.0) |
| Non-smoker | 12 174 (61.0) | 20 525 (60.5) | 2206 (63.3) | 9101 (60.7) | 9968 (60.5) | 11 424 (60.2) |
| No information | 32 (0.2) | 194 (0.6) | 11 (0.3) | 95 (0.6) | 21 (0.1) | 99 (0.5) |
| Comorbidities | ||||||
| Asthma | 1936 (9.7) | 1938 (5.7) | 311 (8.9) | 879 (5.9) | 1625 (9.9) | 1059 (5.6) |
| Chronic kidney disease | 1895 (9.5) | 73 (0.2) | 266 (7.6) | 39 (0.3) | 1629 (9.9) | 34 (0.2) |
| Chronic obstructive pulmonary disease | 752 (3.8) | 689 (2.0) | 116 (3.3) | 347 (2.3) | 636 (3.9) | 342 (1.8) |
| Dementia | 108 (0.5) | 36 (0.1) | 31 (0.9) | 19 (0.1) | 77 (0.5) | 17 (0.1) |
| Depression | 2827 (14.2) | 2238 (6.6) | 409 (11.7) | 963 (6.4) | 2418 (14.7) | 1275 (6.7) |
| Diabetes | 1940 (9.7) | 1305 (3.8) | 343 (9.8) | 695 (4.6) | 1597 (9.7) | 610 (3.2) |
| Dyslipidemia | 2287 (11.5) | 1782 (5.2) | 410 (11.8) | 905 (6.0) | 1877 (11.4) | 877 (4.6) |
| Heart disease | 10 029 (50.3) | 10 261 (30.2) | 1783 (51.1) | 5009 (33.4) | 8246 (50.1) | 5252 (27.7) |
| Hypertension | 10 481 (52.5) | 11 463 (33.8) | 1986 (57.0) | 5845 (39.0) | 8495 (51.6) | 5618 (29.6) |
| Rheumatoid arthritis | 314 (1.6) | 270 (0.8) | 61 (1.7) | 115 (0.8) | 253 (1.5) | 155 (0.8) |
| Hormone levels | ||||||
| Low-normal fT4 levels | 9761 (48.9) | 17 122 (50.4) | 1245 (35.7) | 7014 (46.8) | 8516 (51.7) | 10 108 (53.3) |
| High-normal fT4 levels | 10 191 (51.1) | 16 825 (49.6) | 2241 (64.3) | 7969 (53.2) | 7950 (48.3) | 8856 (46.7) |
| TSH, median (lower quartile-upper quartile) | 3.9 (2.3-5.0) | 4.8 (4.3-5.5) | 3.6 (2.7-4.4) | 4.3 (4.1-4.5) | 4.0 (3.0-5.1) | 5.4 (4.9-6.2) |
Group 1: Patients older than 50 years with a TSH level between 4.0 mU/L and 10.0 mU/L and a normal fT4 level.
Group 1a: Patients older than 50 years with a TSH level between 4.0 mU/L and the age-specific upper limit and a normal fT4 level.
Group 1b: Patients older than 50 years with a TSH level between the age-specific upper limit and 10.0 mU/L and a normal fT4 level.
Low-normal and high-normal fT4 levels are defined as above or below the median fT4 level.
Abbreviations: fT4, free thyroxine; TSH, thyrotropin.
Baseline characteristics of participants of the cardiovascular outcome study
| Characteristic, N (%) . | Group 1, treatment (n = 19 952) . | Group 1, control (n = 33 947) . | Group 1a, treatment (n = 3486) . | Group 1a, control (n = 14 983) . | Group 1b, treatment (n = 16 466) . | Group 1b, control (n = 18 964) . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Female | 15 588 (78.1) | 21 350 (62.9) | 2823 (81.0) | 9502 (63.4) | 12 765 (77.5) | 11 848 (62.5) |
| Male | 4364 (21.9) | 12 597 (37.1) | 663 (19.0) | 5481 (36.6) | 3701 (22.5) | 7116 (37.5) |
| Age, y | ||||||
| 51-60 | 5141 (25.8) | 10 991 (32.4) | 495 (14.2) | 3141 (21.0) | 4646 (28.2) | 7850 (41.4) |
| 61-70 | 6687 (33.5) | 10 309 (30.4) | 895 (25.7) | 4200 (28.0) | 5792 (35.2) | 6109 (32.2) |
| 71-80 | 5185 (26.0) | 8250 (24.3) | 1125 (32.3) | 4654 (31.1) | 4060 (24.7) | 3596 (19.0) |
| 81-90 | 2533 (12.7) | 3895 (11.5) | 813 (23.3) | 2631 (17.6) | 1720 (10.4) | 1264 (6.7) |
| 91+ | 406 (2.0) | 502 (1.5) | 158 (4.5) | 357 (2.4) | 248 (1.5) | 145 (0.8) |
| Median (lower quartile-upper quartile) | 67 (60-76) | 66 (59-75) | 73 (65-81) | 71 (62-79) | 66 (60-75) | 63 (57-71) |
| Ethnicity | ||||||
| Asian | 311 (1.6) | 498 (1.5) | 28 (0.8) | 175 (1.2) | 283 (1.7) | 323 (1.7) |
| Black | 52 (0.3) | 127 (0.4) | 8 (0.2) | 49 (0.3) | 44 (0.3) | 78 (0.4) |
| Mixed | 2937 (14.7) | 5042 (14.9) | 425 (12.2) | 2138 (14.3) | 2512 (15.3) | 2904 (15.3) |
| Other | 89 (0.4) | 178 (0.5) | 20 (0.6) | 81 (0.5) | 69 (0.4) | 97 (0.5) |
| White | 6197 (31.1) | 10 840 (31.9) | 1059 (30.4) | 4674 (31.2) | 5138 (31.2) | 6166 (32.5) |
| No information | 10 366 (52.0) | 17 262 (50.8) | 1946 (55.8) | 7866 (52.5) | 8420 (51.1) | 9396 (49.5) |
| Location | ||||||
| London | 1219 (6.1) | 2154 (6.3) | 182 (5.2) | 830 (5.5) | 1037 (6.3) | 1324 (7.0) |
| Midlands and East | 2972 (14.9) | 4285 (12.6) | 482 (13.8) | 1653 (11.0) | 2490 (15.1) | 2632 (13.9) |
| North | 2889 (14.5) | 4573 (13.5) | 463 (13.3) | 2068 (13.8) | 2426 (14.7) | 2505 (13.2) |
| Northern Ireland | 1380 (6.9) | 1963 (5.8) | 242 (6.9) | 984 (6.6) | 1138 (6.9) | 979 (5.2) |
| Scotland | 2069 (10.4) | 4523 (13.3) | 385 (11.0) | 2139 (14.3) | 1684 (10.2) | 2384 (12.6) |
| South | 4626 (23.2) | 8900 (26.2) | 816 (23.4) | 3700 (24.7) | 3810 (23.1) | 5200 (27.4) |
| Wales | 3212 (16.1) | 5226 (15.4) | 647 (18.6) | 2630 (17.6) | 2565 (15.6) | 2596 (13.7) |
| No information | 1585 (7.9) | 2323 (6.8) | 269 (7.7) | 979 (6.5) | 1316 (8.0) | 1344 (7.1) |
| Smoker status | ||||||
| Smoker | 1510 (7.6) | 2548 (7.5) | 206 (5.9) | 985 (6.6) | 1304 (7.9) | 1563 (8.2) |
| Past smoker | 6236 (31.3) | 10 680 (31.5) | 1063 (30.5) | 4802 (32.0) | 5173 (31.4) | 5878 (31.0) |
| Non-smoker | 12 174 (61.0) | 20 525 (60.5) | 2206 (63.3) | 9101 (60.7) | 9968 (60.5) | 11 424 (60.2) |
| No information | 32 (0.2) | 194 (0.6) | 11 (0.3) | 95 (0.6) | 21 (0.1) | 99 (0.5) |
| Comorbidities | ||||||
| Asthma | 1936 (9.7) | 1938 (5.7) | 311 (8.9) | 879 (5.9) | 1625 (9.9) | 1059 (5.6) |
| Chronic kidney disease | 1895 (9.5) | 73 (0.2) | 266 (7.6) | 39 (0.3) | 1629 (9.9) | 34 (0.2) |
| Chronic obstructive pulmonary disease | 752 (3.8) | 689 (2.0) | 116 (3.3) | 347 (2.3) | 636 (3.9) | 342 (1.8) |
| Dementia | 108 (0.5) | 36 (0.1) | 31 (0.9) | 19 (0.1) | 77 (0.5) | 17 (0.1) |
| Depression | 2827 (14.2) | 2238 (6.6) | 409 (11.7) | 963 (6.4) | 2418 (14.7) | 1275 (6.7) |
| Diabetes | 1940 (9.7) | 1305 (3.8) | 343 (9.8) | 695 (4.6) | 1597 (9.7) | 610 (3.2) |
| Dyslipidemia | 2287 (11.5) | 1782 (5.2) | 410 (11.8) | 905 (6.0) | 1877 (11.4) | 877 (4.6) |
| Heart disease | 10 029 (50.3) | 10 261 (30.2) | 1783 (51.1) | 5009 (33.4) | 8246 (50.1) | 5252 (27.7) |
| Hypertension | 10 481 (52.5) | 11 463 (33.8) | 1986 (57.0) | 5845 (39.0) | 8495 (51.6) | 5618 (29.6) |
| Rheumatoid arthritis | 314 (1.6) | 270 (0.8) | 61 (1.7) | 115 (0.8) | 253 (1.5) | 155 (0.8) |
| Hormone levels | ||||||
| Low-normal fT4 levels | 9761 (48.9) | 17 122 (50.4) | 1245 (35.7) | 7014 (46.8) | 8516 (51.7) | 10 108 (53.3) |
| High-normal fT4 levels | 10 191 (51.1) | 16 825 (49.6) | 2241 (64.3) | 7969 (53.2) | 7950 (48.3) | 8856 (46.7) |
| TSH, median (lower quartile-upper quartile) | 3.9 (2.3-5.0) | 4.8 (4.3-5.5) | 3.6 (2.7-4.4) | 4.3 (4.1-4.5) | 4.0 (3.0-5.1) | 5.4 (4.9-6.2) |
| Characteristic, N (%) . | Group 1, treatment (n = 19 952) . | Group 1, control (n = 33 947) . | Group 1a, treatment (n = 3486) . | Group 1a, control (n = 14 983) . | Group 1b, treatment (n = 16 466) . | Group 1b, control (n = 18 964) . |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Female | 15 588 (78.1) | 21 350 (62.9) | 2823 (81.0) | 9502 (63.4) | 12 765 (77.5) | 11 848 (62.5) |
| Male | 4364 (21.9) | 12 597 (37.1) | 663 (19.0) | 5481 (36.6) | 3701 (22.5) | 7116 (37.5) |
| Age, y | ||||||
| 51-60 | 5141 (25.8) | 10 991 (32.4) | 495 (14.2) | 3141 (21.0) | 4646 (28.2) | 7850 (41.4) |
| 61-70 | 6687 (33.5) | 10 309 (30.4) | 895 (25.7) | 4200 (28.0) | 5792 (35.2) | 6109 (32.2) |
| 71-80 | 5185 (26.0) | 8250 (24.3) | 1125 (32.3) | 4654 (31.1) | 4060 (24.7) | 3596 (19.0) |
| 81-90 | 2533 (12.7) | 3895 (11.5) | 813 (23.3) | 2631 (17.6) | 1720 (10.4) | 1264 (6.7) |
| 91+ | 406 (2.0) | 502 (1.5) | 158 (4.5) | 357 (2.4) | 248 (1.5) | 145 (0.8) |
| Median (lower quartile-upper quartile) | 67 (60-76) | 66 (59-75) | 73 (65-81) | 71 (62-79) | 66 (60-75) | 63 (57-71) |
| Ethnicity | ||||||
| Asian | 311 (1.6) | 498 (1.5) | 28 (0.8) | 175 (1.2) | 283 (1.7) | 323 (1.7) |
| Black | 52 (0.3) | 127 (0.4) | 8 (0.2) | 49 (0.3) | 44 (0.3) | 78 (0.4) |
| Mixed | 2937 (14.7) | 5042 (14.9) | 425 (12.2) | 2138 (14.3) | 2512 (15.3) | 2904 (15.3) |
| Other | 89 (0.4) | 178 (0.5) | 20 (0.6) | 81 (0.5) | 69 (0.4) | 97 (0.5) |
| White | 6197 (31.1) | 10 840 (31.9) | 1059 (30.4) | 4674 (31.2) | 5138 (31.2) | 6166 (32.5) |
| No information | 10 366 (52.0) | 17 262 (50.8) | 1946 (55.8) | 7866 (52.5) | 8420 (51.1) | 9396 (49.5) |
| Location | ||||||
| London | 1219 (6.1) | 2154 (6.3) | 182 (5.2) | 830 (5.5) | 1037 (6.3) | 1324 (7.0) |
| Midlands and East | 2972 (14.9) | 4285 (12.6) | 482 (13.8) | 1653 (11.0) | 2490 (15.1) | 2632 (13.9) |
| North | 2889 (14.5) | 4573 (13.5) | 463 (13.3) | 2068 (13.8) | 2426 (14.7) | 2505 (13.2) |
| Northern Ireland | 1380 (6.9) | 1963 (5.8) | 242 (6.9) | 984 (6.6) | 1138 (6.9) | 979 (5.2) |
| Scotland | 2069 (10.4) | 4523 (13.3) | 385 (11.0) | 2139 (14.3) | 1684 (10.2) | 2384 (12.6) |
| South | 4626 (23.2) | 8900 (26.2) | 816 (23.4) | 3700 (24.7) | 3810 (23.1) | 5200 (27.4) |
| Wales | 3212 (16.1) | 5226 (15.4) | 647 (18.6) | 2630 (17.6) | 2565 (15.6) | 2596 (13.7) |
| No information | 1585 (7.9) | 2323 (6.8) | 269 (7.7) | 979 (6.5) | 1316 (8.0) | 1344 (7.1) |
| Smoker status | ||||||
| Smoker | 1510 (7.6) | 2548 (7.5) | 206 (5.9) | 985 (6.6) | 1304 (7.9) | 1563 (8.2) |
| Past smoker | 6236 (31.3) | 10 680 (31.5) | 1063 (30.5) | 4802 (32.0) | 5173 (31.4) | 5878 (31.0) |
| Non-smoker | 12 174 (61.0) | 20 525 (60.5) | 2206 (63.3) | 9101 (60.7) | 9968 (60.5) | 11 424 (60.2) |
| No information | 32 (0.2) | 194 (0.6) | 11 (0.3) | 95 (0.6) | 21 (0.1) | 99 (0.5) |
| Comorbidities | ||||||
| Asthma | 1936 (9.7) | 1938 (5.7) | 311 (8.9) | 879 (5.9) | 1625 (9.9) | 1059 (5.6) |
| Chronic kidney disease | 1895 (9.5) | 73 (0.2) | 266 (7.6) | 39 (0.3) | 1629 (9.9) | 34 (0.2) |
| Chronic obstructive pulmonary disease | 752 (3.8) | 689 (2.0) | 116 (3.3) | 347 (2.3) | 636 (3.9) | 342 (1.8) |
| Dementia | 108 (0.5) | 36 (0.1) | 31 (0.9) | 19 (0.1) | 77 (0.5) | 17 (0.1) |
| Depression | 2827 (14.2) | 2238 (6.6) | 409 (11.7) | 963 (6.4) | 2418 (14.7) | 1275 (6.7) |
| Diabetes | 1940 (9.7) | 1305 (3.8) | 343 (9.8) | 695 (4.6) | 1597 (9.7) | 610 (3.2) |
| Dyslipidemia | 2287 (11.5) | 1782 (5.2) | 410 (11.8) | 905 (6.0) | 1877 (11.4) | 877 (4.6) |
| Heart disease | 10 029 (50.3) | 10 261 (30.2) | 1783 (51.1) | 5009 (33.4) | 8246 (50.1) | 5252 (27.7) |
| Hypertension | 10 481 (52.5) | 11 463 (33.8) | 1986 (57.0) | 5845 (39.0) | 8495 (51.6) | 5618 (29.6) |
| Rheumatoid arthritis | 314 (1.6) | 270 (0.8) | 61 (1.7) | 115 (0.8) | 253 (1.5) | 155 (0.8) |
| Hormone levels | ||||||
| Low-normal fT4 levels | 9761 (48.9) | 17 122 (50.4) | 1245 (35.7) | 7014 (46.8) | 8516 (51.7) | 10 108 (53.3) |
| High-normal fT4 levels | 10 191 (51.1) | 16 825 (49.6) | 2241 (64.3) | 7969 (53.2) | 7950 (48.3) | 8856 (46.7) |
| TSH, median (lower quartile-upper quartile) | 3.9 (2.3-5.0) | 4.8 (4.3-5.5) | 3.6 (2.7-4.4) | 4.3 (4.1-4.5) | 4.0 (3.0-5.1) | 5.4 (4.9-6.2) |
Group 1: Patients older than 50 years with a TSH level between 4.0 mU/L and 10.0 mU/L and a normal fT4 level.
Group 1a: Patients older than 50 years with a TSH level between 4.0 mU/L and the age-specific upper limit and a normal fT4 level.
Group 1b: Patients older than 50 years with a TSH level between the age-specific upper limit and 10.0 mU/L and a normal fT4 level.
Low-normal and high-normal fT4 levels are defined as above or below the median fT4 level.
Abbreviations: fT4, free thyroxine; TSH, thyrotropin.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
